Articles tagged "Efficacy"

2022 American Transplant Congress
Mhealth Coaching Improves Patient Activation and Nutritional Behaviors in Diverse Renal Transplant Recipients
M. Pollack¹, N. Stauffer², H. Lee², I. Satoru², M. Ellis³, C. Diamantidis³, S. Docherty⁴, E. T. Chambers⁵
¹Psychiatry, Duke University, Durham, NC, ²Biostatistics, Duke University, Durham, NC, ³Internal Medicine, Duke University, Durham, NC, ⁴School of Nursing, Duke University, Durham, NC, ⁵Pediatrics, Duke University, Durham, NC
*Purpose: Kidney transplant recipients who are not actively engaged in their care and lack self-management skills have poor transplant outcomes. These suboptimal outcomes are disproportionately…
2022 American Transplant Congress
Outcomes of Very Small Pediatric Donor Kidneys Utilizing Belatacept-Based Immunosuppression in Adult Recipients
K. Heinen¹, A. Carlson², A. Chan¹, M. M. Eiting¹, T. Larson¹, B. Sirandas¹, C. Truax¹, L. Smith¹
¹University of Utah Health, Salt Lake City, UT, ²Medical University of South Carolina, Johnston, SC
*Purpose: Due to the lack of data utilizing belatacept as primary immunosuppression for adult recipients of very small pediatric donor kidneys, this study seeks to…
2022 American Transplant Congress
Long-Term Effects of Conversion from Calcineurin Inhibitors to Sirolimus for the Recipients with Low Immunological Risk in Renal Allograft
Q. Wu, J. Chen, D. Cheng, X. Ni, X. Li, K. Xie, W. Jiqiu
National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University Jinling School of Medicine, Nanjing, China
*Purpose: To observe the long-term effects and prognosis of conversion from calcineurin inhibitors (CNIs) to sirolimus in biopsy-proven low immunological risk renal transplant recipients (RTRs).*Methods:…
2022 American Transplant Congress
Real-Life Prevention of Breakthrough SARS-CoV-2 Infections by mRNA Vaccines in Kidney Transplant Recipients vs Hemodialysis Patients
D. Rodríguez-Espinosa, E. Montagud-Marrahi, J. Cacho, C. Arana, N. Taurizano, E. Hermida, J. Del Risco, J. Casals, A. Rosario, E. Cuadrado, N. Rodríguez, I. Revuelta, B. Bayès, P. Ventura-Aguiar, F. Cofan, E. Poch, F. Oppenheimer, M. Vera, L. Rodas, F. Maduell, F. Diekmann, A. Cases, J. Broseta, D. Cucchiari
Nephrology and Renal Transplantation, Hospital Clinic of Barcelona, Barcelona, Spain
*Purpose: The increased COVID-19 severity observed in kidney transplant recipients (KTR) has been widely reported. In addition, several studies have shown a reduced humoral and…
2022 American Transplant Congress
Efficacy and Safety of Denosumab on Osteoporosis in Kidney Transplant Recipients
W. Park, J. Kwon, J. Lim, Y. Kim, J. Paek, K. Jin, S. Han
Division of Nephrology, Department of Internal Medicine, Keimyung University School of Medicine, Keimyung University Dongsan Hospital, Daegu, Korea, Republic of
*Purpose: The use of immunosuppressive agents, especially glucocorticoids, are associated with increased risks of bone loss in kidney transplant recipients (KTRs). Denosumab, a potent antiresorptive…
2021 American Transplant Congress
Automated Electronic Donor Referrals Have Increased Transplantation
J. Piano
Transplant Connect, Santa Monica, CA
*Purpose: It is well understood and supported by previous studies that costly inefficiencies exist in the current phone-based process by which hospitals refer potential donors…
2021 American Transplant Congress
Efficacy of MAU868, a Novel BKV Neutralizing Monoclonal Antibody (mAb), for the Treatment of Severe BK Virus Nephropathy (BKVN) After Kidney Transplant
S. C. Jordan¹, N. Ammerman², M. Toyoda³, K. Lim², J. R. Abend⁴, A. Patick⁵, M. R. Hodges⁵, A. Vo², S. J. Kovacs⁶
¹Comprehensive Transplant Center, Cedars Sinai Medical Ctr, West Hollywood, CA, ²Comprehensive Transplant Center, Cedars Sinai Medical Ctr, Los Angeles, CA, ³Cedars Sinai Medical Ctr, Los Angeles, CA, ⁴Novartis Institutes for BioMedical Research, Virology Research, Emeryville, CA, ⁵Amplyx Pharmaceuticals, San Diego, CA, ⁶Novartis Institutes for BioMedical Research, Translational Medicine, East Hanover, NJ
*Purpose: BKV reactivation leading to nephropathy and allograft loss in kidney transplant (KT) recipients remains a clinical significant concern. No specific or effective anti-BKV therapies…
2021 American Transplant Congress
Successful Prophylaxis of Antibody-Mediated Rejection by Downregulation of C5 Expression via RNA Interference in a Rat Kidney Transplant Model
H. Ishigooka¹, S. Motoi², T. Yamakawa¹, C. Matsui², Y. Suzuki³, R. Ishii¹, K. Saiga¹, D. Tokita¹, T. Imai², K. Tanabe¹
¹Urology, Tokyo Women's Medical University, Tokyo, Japan, ²KAN Research Institute, Inc., Kobe, Japan, ³Tsukuba Research Laboratories, Eisai, Co., Ltd., Ibaraki, Japan
*Purpose: Antibody-mediated rejection (AMR) is a major contributor towards poor prognosis in kidney transplantation. Circulating donor-specific antibodies (DSAs) cause AMR with complement activation. This study…
2021 American Transplant Congress
Versatile Strategy to Enhance Nanomedicine Delivery to Graft Endothelial Cells
C. Albert¹, L. G. Bracaglia¹, A. Koide², J. DiRito¹, T. Lysyy¹, C. Edwards¹, J. T. Langford¹, D. Haakinson¹, S. A. Hosgood³, M. L. Nicholson³, J. S. Pober¹, W. M. Saltzman¹, S. Kiode², G. Tietjen¹
¹Yale University, new haven, CT, ²Perlmutter Cancer Center, New York University, Langone Medical Center, New York, NY, ³University of Cambridge, Cambridge, United Kingdom
*Purpose: Efficient delivery of therapeutics to graft endothelial cells (EC) can potentially render organs more resistant to injury, improving clinical outcomes. Specific targeting of polymeric…
2021 American Transplant Congress
Utilizing Risk Factors to Guide Prevention of Invasive Fungal Infections in Liver Transplant Recipients
K. Fitton, A. Chan, C. Truax, B. Sirandas, T. Larson, L. Smith, A. Carlson
University of Utah Health, Salt Lake City, UT
*Purpose: Invasive fungal infection (IFI) after liver transplant (LT) is associated with significant morbidity and mortality. The optimal antifungal prophylaxis regimen has not been defined.…